Ubiquitin-interaction motifs of RAP80 are critical in its regulation of estrogen receptor α

Jun Yan¹, Yong-Sik Kim¹, Xiao-Ping Yang¹, Michael Albers², Manfred Koegel³ and Anton M. Jetten¹,*

¹Cell Biology Section, Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA, ²Phenex Pharmaceuticals AG, D-67056 Ludwigshafen, Germany and ³RZPD German Resource Center for Genome Research, D-69120 Heidelberg, Germany

ABSTRACT

In this study, we demonstrate that receptor-associated protein 80 (RAP80) interacts with estrogen receptor alpha (ERα) in an agonist-dependent manner. The interaction is specific for ERα as ERβ and several other nuclear receptors tested did not interact with RAP80. Interaction between RAP80 and ERα was supported by mammalian two-hybrid, GST pull-down, and co-immunoprecipitation analyses. The hinge/ligand-binding domain of ERα is sufficient for interaction with RAP80. RAP80 overexpression reduces ERα polyubiquitination, increases the level of ERα protein, and enhances ERα-mediated transactivation. Knockdown of endogenous RAP80 expression by small-interfering RNA (siRNA) reduced ERα protein level and the E2-dependent induction of pS2. In this study, we also demonstrate that RAP80 contains two functional ubiquitin-interaction motifs (UIMs) that are able to bind ubiquitin and to direct monoubiquitination of RAP80. Deletion of these UIMs does not affect the ability of RAP80 to interact with ERα, but eliminates the effects of RAP80 on ERα polyubiquitination, the level of ERα protein, and ERα-mediated transcription. These data indicate that the UIMs in RAP80 are critical for the function of RAP80. Our study identifies ERα as a new RAP80-interacting protein and suggests that RAP80 may be an important modulator of ERα activity.

INTRODUCTION

Estrogens are important for a number of physiological processes that include various reproductive functions and bone metabolism (1–3). The biological actions of estrogens are primarily mediated by two high-affinity nuclear receptors, estrogen receptor α and β (ERα and ERβ) (3,4). In the classical model of nuclear receptor action, ER binding of estrogen releases the receptor from inactive complexes containing heat-shock proteins and immunophilins, followed by dimerization, and binding of ER homodimers to estrogen-response elements (EREs) in the regulatory regions of target genes. Agonist binding induces a conformational change including a repositioning of helix 12 which represents the ligand-inducible activation function AF-2 (3–7). This allows recruitment of co-activator complexes that cause decompaction of chromatin through their histone acetylase activity and transcriptional activation of target genes. In addition to co-activators, a large number of other proteins that interact with ERα and modify its transcriptional activity have been identified (8–12). Moreover, various posttranslational modifications, including phosphorylation, sumoylation and ubiquitination, have been reported to modulate ERα activity (9,13–16). Polyubiquitination and degradation of ERα and other nuclear receptors by the ubiquitin–proteasome system is important for regulating nuclear receptor levels and their transcriptional activities (14,16–21). Several components of the ubiquitin-proteasome degradation system, such as PSMC5 (SUG/TRIP1) (22), RSP5/RPF1 (23), UBCH7 (24) and CHIP (16), have been reported to interact with a number of nuclear receptors, including ERα. Recently, sumoylation has been identified as another mechanism that regulates the transcriptional activity of ERα and was shown to involve UBC9, PIAS1 and PIAS3 (9,25). However, our knowledge about the mechanisms by which ubiquitination and sumoylation regulate nuclear receptor level and activity is still far from complete.

We recently described the identification of a novel protein, referred to as receptor-associated protein 80 (RAP80) or ubiquitin interaction motif containing 1 (UIMC1) as approved by the HUGO Gene Nomenclature Committee (26). RAP80 is an acidic nuclear protein of 719 amino acids that contains two Cys-X2-Cys-X11-His-X3-Cys zinc finger-like motifs near
the carboxyl terminus. RAP80 is expressed in many tissues, most abundantly in testis. RAP80 was shown to interact with the retinoid-related testis-associated receptor (RTR), also known as germ cell nuclear factor (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 in modulating the activity of other nuclear receptors. Yeast two-hybrid analysis demonstrated that RAP80 interacted with ERα, but not with ERβ or several other nuclear receptors. This interaction required the presence of an agonist, such as estrogen, while antagonists did not induce the interaction. RAP80 was found to contain nuclear receptors. This interaction required the presence of ERα in modulating the activity of other nuclear receptors. The pcDNA3.1–RAP80 interacted with ERα in modulating the activity of other nuclear receptors. The study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29). The objective of the current study was to determine the potential role of RAP80 (GCNF) or NR6A1 (26–29).

**MATERIALS AND METHODS**

**Plasmids**

The yeast and mammalian two-hybrid vectors pGBK7, pGBT9, pGADT7, pM, pVP16, and the retroviral vector pLXIN were purchased from BD Biosciences (Palo Alto, CA). The reporter plasmid pFR-Luc, containing 5 copies of the GAL4 upstream-activating sequence (UAS), referred to as (UAS)5-Luc, was obtained from Stratagene (La Jolla, CA). pcDNA3.1 and pcDNA3.1(–)Mye-His were purchased from Invitrogen (Carlsbad, CA) and pCMV–3×FLAG–7.1 from Sigma (St. Louis, MO). PhRL–SV40 encoding the Renilla luciferase was obtained from Promega (Madison, WI). To create pGADT7–RAP80ΔN135, the region encoding aa 135 to the carboxyl terminus, was amplified by PCR and the amplified product was inserted into the EcoRI and BamHI sites of pGADT7. RAP80ΔN129 and full-length ERα were inserted in-frame into EcoRI and BamHI sites of pM and pVP16, respectively, for use in mammalian two-hybrid assays. The ERE–CAT reporter, in which the CAT reporter is under the control of the natural ERE from the VitA2 promoter, was a gift from Dr Christina Teng (NIEHS). The ERα expression vector pERα and the (ERE)×3–Luc reporter were kindly provided by Dr Donald McDonnell (Duke University). The pcDNA3.1–RAP80 was generated by inserting full-length RAP80 into the expression vector pcDNA3.1. pLXIN–3×FLAG–RAP80 was constructed by inserting 3×FLAG–RAP80 into the vector pLXIN. pcDNA3.1–ERα–Mye-His plasmids containing either full-length ERα, ERαΔN180, ERαΔN248 or ERαΔC248 were generated by inserting the corresponding coding regions, obtained by PCR amplification, into the EcoRI and BamHI sites of pcDNA3.1(–)Mye-His. The pLXIN–3×FLAG–RAP80 mutants K90R, K112R and K90,112R were generated using a Quickchange site-directed mutagenesis kit (Stratagene). The pLXIN–3×FLAG–RAP80 mutants ΔUIM1, ΔUIM2 and ΔUIM1,2, in which the regions encoding the UIM1, UIM2 or both were deleted, were generated by PCR amplification. The regions up- and down-stream from the UIMs were first amplified by PCR, then ligated at the introduced XhoI sites, and subsequently inserted into the EcoRI and BamHI sites of pLXIN–3×FLAG. The pLXIN–3×FLAG–RAP80ΔC122 mutants A88S, A113S and A88,113S were generated with a Quickchange site-directed mutagenesis kit. PEGFP–UIM1,2 was constructed by inserting the UIMs of RAP80 into EcoRI and BamHI sites of pEGFP-C1. pGEX–UIM1,2 was constructed by inserting the UIMs of RAP80 into EcoRI and BamHI sites of pGEX–5×-3. pCMV–HA–Ub, encoding HA–ubiquitin, and pcDNA3–HA–Nedd8 were gifts from Dr Yue Xiong (University of North Carolina, Chapel Hill, NC).

**Yeast two-hybrid screening**

Briefly, *Saccharomyces cerevisiae* Y187 (MATz) were transformed with pGADT7–RAP80 (FL) or pGADT7ΔN129 plasmid DNA. pGBT9 plasmid DNAs, encoding the ligand-binding domain or the full-length coding region of various nuclear receptors, were provided by Dr Michael Albers (PheneX-Pharmaceuticals, Heidelberg), pGBT9 plasmids were transformed into *S. cerevisiae* strain AH109(MATa). After mating, double transformants were selected in minimal Synthetic Dropout medium (SD-Trp-Leu). The transformants were then grown in SD-Leu-Trp-His containing 50 µM 4-methylumbelliferyl α-d-galactopyranoside (4-MuX) (Sigma) in the presence or absence of corresponding ligand. The mixture was incubated for 48 h and fluorescence measured (excitation 360 nm, emission 465 nm wavelength). pGADT7–p53, encoding GAL4 DNA-binding domain (DBD)–p53, and pGADT7–TD1–1, encoding the GAL4-activation domain fused to the SV40 large T antigen, were used as a positive control in yeast two-hybrid analysis.

**GST pull-down assay**

*E. coli* BL21 cells (Stratagene) transformed with pGEX or pGEX–RAP80ΔN110 plasmid DNA were grown at 37°C to mid-log phase. Synthesis of GST or GST fusion protein was then induced by the addition of isopropyl-thiogalactopyranoside (IPTG; 0.5 mM final concentration) at 37°C.
After 4 h of incubation, cells were collected, resuspended in BugBuster protein extraction reagent (Novagen, Madison, WI) and processed according to the manufacturer’s protocol. Cellular extracts were then centrifuged at 15,000 × g, and the supernatants containing the soluble GST proteins were collected. Equal amounts of GST–RAP80ΔN110 protein or GST protein were incubated with glutathione-Sepharose 4B beads and washed in phosphate-buffered saline. [35S]-methionine-labeled ERα and its deletion mutants were generated using the TNT Quick Coupled Transcription/Translation system (Promega). The GST- and GST–RAP80ΔN110-bound beads were then incubated with [35S]-methionine-labeled ERα in 0.5 ml binding buffer (20 mM Tris-HCl, pH 7.6, 100 mM KCl, 0.05% Nonidet P-40, 0.1 mM EDTA, 10% glycerol, 1 mM PMSF) in the presence or absence of 1 μM E2. After 1 h incubation at room temperature, beads were washed five times in binding buffer and boiled in 15 μl 2× SDS-PAGE loading buffer. Solubilized proteins were separated by 4–12% SDS-PAGE and the radiolabeled proteins visualized by autoradiography. To analyze ubiquitin binding, 500 ng of a mixture of polyubiquitin chains (Ub2-7) (Biomol, Plymouth Meeting, PA) were incubated with purified GST or GST–UIM RAP80 protein. GST protein complexes were isolated with glutathione-Sepharose 4B beads and examined by western blot analysis with an anti-ubiquitin antibody (Covance).

Co-immunoprecipitation assay

HeLa cells were transiently transfected with pLXIN-3×FLAG–RAP80 (full-length or mutant) and pcDNA3.1–ERα–Myc-His or pERα, as indicated, using Fugene 6 transfection reagent (Roche, Indianapolis, IN). Forty-eight hours after transfection, cells were harvested and lysed for 1 h in NP40 lysis buffer (150 mM NaCl, 0.5% NP40, 50 mM NaF, 50 mM Tris-HCl, pH 8.0) containing protease inhibitor cocktails I and II (Sigma). The cell lysates were centrifuged at 14,000 × g at 4°C for 10 min. The supernatants were then incubated with anti-FLAG M2 affinity resin overnight to isolate FLAG–RAP80 protein complexes. The resin was washed three times with lysis buffer. The bound protein complexes were then solubilized in sample buffer and analyzed by western blot analysis using anti-ERα (Santa Cruz) and anti-FLAG M2 (Sigma) antibodies.

Ubiquitination assay

HeLa cells were transiently transfected with pcDNA3.1–ERα–Myc-His, pLXIN-3×FLAG–RAP80 or pLXIN-3×FLAG–RAP80ΔUIM1,2 and pcMV–HA–Ub. Forty-four hours after transfection, cells were treated with 25 μM MG132 or ethanol for 4 h. Cells were then harvested and lysed for 1 h in modified RIPA buffer (50 mM Tris-HCl (pH 7.8), 150 mM NaCl2, 5 mM EDTA, 15 mM MgCl2, 0.5% NP-40, 0.3% Triton X-100, 0.5% sodium deoxycholate, 1 mM dithiothreitol, 10 mM N-ethylmaleimide and 0.1% SDS) containing protease inhibitor cocktails. The cell lysates were centrifuged at 14,000 × g at 4°C for 10 min. The supernatants were incubated with anti-ERα antibody and protein-G agarose (Sigma) overnight to pull down ERα protein complexes. The agarose was then washed three times with lysis buffer. The bound proteins were solubilized in sample buffer and analyzed by western blot analysis using anti-HA (Sigma) and anti-ERα antibodies.

Reporter gene assay

CHO and MCF-7 cells were maintained in phenol red-free F12 or RPMI 1640 supplemented with 10% charcoal-stripped fetal bovine serum (Sigma). Cells were transfected using Fugene 6 transfection reagent with the reporter plasmids pERE–CAT or (ERE)2-Luc, RAP80 and ERα expression vectors, and the internal standard β-galactosidase expression vector or phRL–SV40, as indicated. Five hours after transfection, the medium was replaced and 16 h later agonists or antagonists (Sigma) were added. After an additional 24 h incubation, cells were harvested in passive lysis buffer (Promega) and the level of luciferase or CAT protein measured using the Dual-Luciferase® Reporter Assay System (Promega) or CAT-ELISA kit (Roche). All analyses were performed in triplicate.

RAP80 knockdown

MCF-7 cells were transfected with scrambled or RAP80 SMARTpool siRNA reagent (Dharmacon) according to the manufacturer’s instructions. Cells were maintained in phenol red-free RPMI 1640 supplemented with 10% charcoal-stripped fetal bovine serum (Sigma) for 48 h, followed by a 24 h treatment with E2. Cells were then collected, protein lysates prepared and examined by western blot analysis using antibodies against RAP80 (Bethyl, TX), pS2 (Santa Cruz), ERα and actin.

RESULTS

Identification of ERα as a new RAP80-interacting protein

Earlier, we demonstrated that the nuclear protein RAP80 interacts with and modulates the activity of the nuclear orphan receptor RTR/GCNF (26). To determine whether RAP80 was able to interact with other nuclear receptors, we performed yeast two-hybrid analysis using RAP80 as prey and several full-length nuclear receptors or their ligand-binding domains as bait. The yeast strain AH109(MATa) was transformed with pGBT9 plasmids encoding various nuclear receptors and then mated with Y187(MATα) containing pGADT7–RAP80ΔN110. The potential interactions between RAP80 and nuclear receptors were analyzed in the presence or absence of corresponding ligand. This analysis identified ERα as a new RAP80-binding partner and demonstrated that this interaction required the presence of the ERα agonist 17β-estradiol (E2) (Figure 1A). In the presence of E2, RAP80 was able to interact with both full-length ERα and the ligand-binding domain of ERα (ERα(LBD)) suggesting that the amino terminus, including the DNA-binding domain (DBD), is not an absolute requirement for the interaction. RAP80 did not show any substantial interaction with the vitamin D receptor (VDR), androgen receptor (AR), liver X receptor α (LXRα), retinoid X receptor α (RXRα), peroxisome
proliferator receptor γ (PPARγ), or retinoic acid receptor γ (RARγ) either in the presence or absence of corresponding ligand. The RORγ receptor, which appears to be constitutively active, also did not interact with RAP80.

As shown in Figure 1B, the interaction of RAP80 with full-length ERx was dependent on the concentration of E2. A concentration as low as 0.2 nM E2 was able to induce the interaction between RAP80 and ERx. The EC50 was calculated to be 1.9 nM E2. RAP80 did not interact with full-length ERβ (Figure 1B) or ERβ(LBD) (not shown) either in the presence or absence of E2. These observations indicate that the interaction of RAP80 with nuclear receptors is highly selective for ERx and is ligand dependent.

**Mammalian two-hybrid analysis**

The interaction of RAP80 with ERx was confirmed by mammalian two-hybrid analysis. CHO cells were co-transfected with (UAS)x-Luc reporter, pM–RAP80, increasing amounts of pVP16–ERx and pcDNA3.1–RAP80 as indicated. Sixteen hours later cells were treated with 100 nM E2 or vehicle. Cells were assayed for reporter activity 24 h after the addition of E2. The relative Luc activity was calculated and plotted. (B) Agonists but not antagonists induce interaction between RAP80 and ERx. CHO cells were co-transfected with pM–RAP80AN130, pVP16–ERx and pS5–CAT reporter. Cells were treated with different agonists or antagonists (1 μM) as indicated. Cells were assayed for the reporter activity 24 h after transfection. Ligands used: E2, 17β-estradiol; Tam, tamoxifen; ICI, ICI 182,780; E3, estriol; ZZ-dienestrol; DES, diethylstilbestrol.

Figure 1. RAP80 interacts selectively with ERx. The interaction of RAP80 with different nuclear receptors was analyzed by yeast two-hybrid analysis as described in Materials and Methods. RAP80 was used as bait and several full-length (FL) nuclear receptors or their LBD were used as prey. (A) The interaction of RAP80 with different nuclear receptors was analyzed in the presence (+) or absence (−) of corresponding agonist. The following agonists were used: 1,25-dihydroxyvitamin D3 (100 nM) for VDR; dihydrotestosterone (100 nM) for AR; T0901317 (1 μM) for LXRx; GW845 (100 nM) for PPARγ; 17β-estradiol (100 nM) for ERα(FL) and ERα(LBD); the RXR-panagonist SR11217 (1 μM); retinoic acid (1 μM) for RARγ.

Figure 2. Analysis of the interaction between RAP80 and ERx by mammalian two-hybrid analysis. (A) CHO cells were co-transfected with (UAS)x-Luc reporter, pM–RAP80, increasing amounts of pVP16–ERx and pcDNA3.1–RAP80 as indicated. Sixteen hours later cells were treated with 100 nM E2 or vehicle. Cells were assayed for reporter activity 24 h after the addition of E2. The relative Luc activity was calculated and plotted. (B) Agonists but not antagonists induce interaction between RAP80 and ERx. CHO cells were co-transfected with pM–RAP80AN130, pVP16–ERx and pS5–CAT reporter. Cells were treated with different agonists or antagonists (1 μM) as indicated. Cells were assayed for the reporter activity 24 h after transfection. Ligands used: E2, 17β-estradiol; Tam, tamoxifen; ICI, ICI 182,780; E3, estriol; ZZ-dienestrol; DES, diethylstilbestrol.
GAL4(DBD)–RAP80 with pVP16–ERz only slightly increased reporter activity, while addition of E2 greatly induced this reporter activity. Co-transfection with the expression plasmid pcDNA3.1–RAP80 totally abrogated this induction due to competition of RAP80 with GAL4(DBD)–RAP80AN129 for ERz binding. These observations support our conclusion that RAP80 interacts with ERz in an E2-dependent manner.

We next compared the effect of several ER agonists and antagonists on the interaction of RAP80 with ERz. CHO cells were co-transfected with pM–RAP80/C1, pVP16–ERz, and the pSS–CAT reporter plasmid containing five tandem GAL4-binding elements. Sixteen hours later cells were treated with various (ant)agonists. As shown in Figure 2B, all agonists tested, E2, estriol (E3) and diethylstilbestrol (DES), induced the interaction of ERz with RAP80. The weak agonist ZZ-dienestrol also induced the interaction; however, treatment with the antagonists tamoxifen (Tam) and ICI 182,780 (ICI) did not promote the interaction between ERz and RAP80. These results indicate that the interaction of RAP80 with ERz is dependent on the presence of an ERz agonist. Thus, only RAP80 interacts with a transcriptionally active form of ERz.

Co-immunoprecipitation and GST pull-down analysis

To investigate this interaction further, we performed co-immunoprecipitation analysis. HeLa cells were co-transfected with pCDNA3.1–ERz–Myc-His and pLXIN–3×FLAG–RAP80–expression plasmids, treated with 100 nM E2 or ethanol (vehicle) before cells were harvested and cell lysates prepared. Part of the cell lysates was used directly for western blot analysis while the remaining was incubated with anti-FLAG M2 affinity resin to isolate FLAG–RAP80 protein complexes. As shown in Figure 3A, ERz was immunoprecipitated with FLAG–RAP80 only when E2 was present. These observations are in agreement with the conclusion that RAP80 and ERz interact with each other in an agonist-dependent manner.

We next examined whether E2 was able to induce the interaction between endogenous ERz and RAP80. MCF–7 cells were treated with or without E2 or ICI 182,780 for 3 h before nuclear lysates were prepared. RAP80 protein complexes were then immunoprecipitated using an anti-RAP80 antibody and the immunoprecipitated RAP80 protein complexes were examined by western blot analysis with an anti-ERz antibody. Figure 3B shows that endogenous ERz and RAP80 interact with each other. ERz was found in complex with RAP80 only in the presence of E2. The association between ERz and RAP80 was confirmed by analysis of ERz protein complexes immunoprecipitated with an anti-ERz antibody (Figure 3C).

We next examined the interaction of RAP80 with ERz by in vitro pull-down analysis using purified GST–RAP80AN110 fusion protein and [35S]labeled full-length ERz. This analysis showed little interaction between RAP80 and ERz in the absence of E2 (Figure 3D); however, significant binding of ERz to RAP80 was observed in the presence of E2. GST alone did not bind ERz either in the presence or absence of E2. To examine which region of ERz was required for this interaction with RAP80, GST pull-down analysis was performed with three ERz deletion mutants, ERzΔN248, ERzΔN180 and ERzΔC248. As shown in Figure 3E, in the presence of E2, RAP80 was able to bind ERzΔN180 and ERzΔN248, but not ERzΔC248. These results demonstrate that the amino terminus of ERz is unable to bind RAP80 and that the LBD of ERz is required and sufficient for interaction with RAP80. In addition, these observations suggest that RAP80 physically interacts with ERz.

Effect of various deletions in RAP80 on its interaction with ERz

RAP80 contains two putative zinc finger-like motifs at its carboxyl terminus, between aa 505 and 582. To determine which region of RAP80 was important for its interaction with ERz, we constructed a series of carboxyl-terminal deletion mutants (Figure 4A) and examined their ability to interact with ERz by co-immunoprecipitation analysis (Figure 4B). The results demonstrated that carboxyl-terminal deletions up to aa 504 had little effect on the ability of RAP80 to bind ERz, while RAP80ΔC404 was still able to co-immunoprecipitate ERz but less efficiently. In contrast, RAP80ΔC304 and likewise the more severe deletion mutants RAP80ΔC204 and RAP80ΔC122 were unable to interact with ERz. These observations indicate that the region of RAP80 between aa 304 and 404 is critical for the interaction with ERz and that the carboxyl-terminal zinc finger-like motifs are not required. Although several amino-terminal deletions of RAP80 were constructed, none of amino-truncated proteins were expressed in cells. This might be due to improper folding of these mutants and their rapid degradation by the proteasome system.

Effect of RAP80 on ERz-mediated transcriptional activation

To examine the functional significance of the RAP80–ERz interaction, we determined whether RAP80 had any effect on the transcriptional activity of endogenous ERz. MCF–7 cells were co-transfected with an (ERE)3–Luc reporter and different amounts of RAP80 expression vector, and then treated with or without E2. As demonstrated in Figure 5, RAP80 increased E2-induced transcriptional activation by endogenous ERz. In contrast to full-length RAP80, the deletion mutant RAP80ΔC204, which does not interact with ERz, had no effect on ERz transcriptional activity. An increase in ERz-mediated transactivation was also observed in CHO cells transfected with an ERE–CAT reporter plasmid, and ERz and/or RAP80 expression plasmids (Figure S1A). E2 induced reporter activity in cells transfected with the ERz expression vector, this activation was further increased by 3-fold in cells co-transfected with the RAP80 expression vector. To determine whether this increase was specific for ERz-mediated transactivation or whether RAP80 affected the general transcriptional machinery, the effect of RAP80 on RORE-dependent transcriptional activation by RORγ, a nuclear receptor that does not interact with
RAP80, was examined. Figure S1B shows that RAP80 had no effect on RORγ-mediated transactivation.

**RAP80 expression affects ERα protein levels**

To examine whether RAP80 had any effect on the level of ERα protein, HeLa cells were transfected with the expression vector pERα in the presence or absence of pLXIN–3×FLAG–RAP80. As shown in Figure 6A, the level of ERα protein was very low in HeLa cells transfected with pERα only. In cells co-expressing RAP80 and ERα, the level of total ERα protein was greatly enhanced but only in cells treated with E2. Similar results were obtained with ERα protein co-immunoprecipitated by FLAG–RAP80. These observations suggest that expression of RAP80 enhances the
level of ERα protein and that this increase is dependent on the presence of an agonist. This enhancement in ERα protein was not due to an increase in the levels of ERα mRNA by RAP80 since levels of ERα mRNA were very similar between MCF-7 and MCF-7–RAP80 (Figure S2).

We next examined the effect of RAP80 knockdown by RAP80 small-interfering RNA (siRNA) on endogenous ERα protein in MCF-7 cells (Figure 6B). As reported earlier (31,35), treatment with E2 reduced ERα levels (compare lanes 1 and 2), this reduction was more pronounced in cells in which RAP80 was down-regulated (compare lanes 2 and 4). Little difference in ERα levels was observed between untreated cells (lanes 1 and 3). These data are in agreement with our conclusion that RAP80 enhances the level of ERα protein. To analyze the effect of RAP80 knockdown on the transcriptional activity of ERα, we examined its effect on the induction of the ERα target gene pS2. As shown in Figure 6B, the induction of pS2 protein was significantly less in cells in which RAP80 expression was reduced in agreement with our observations that increased RAP80 expression enhances ERα activity.
RAP80 contains two functional ubiquitin-interacting motifs (UIMs)

A more extensive analysis of the RAP80 sequence showed that, in addition to the two zinc finger motifs, RAP80 contained two putative ubiquitin-interacting motifs (UIMs) at its amino terminus of RAP80 between aa 79-96 and 104-121, respectively. These UIMs (UIM\textsuperscript{RAP80}) exhibit high homology with the consensus UIM (Figure 7A). UIMs have been reported to bind ubiquitin and to direct (multi)monoubiquitination of proteins that contain them (31,35). Before investigating the role of UIM\textsuperscript{RAP80} in the interaction of RAP80 with ER\textsubscript{a}, we examined whether these putative UIMs were functional by determining their ability to bind ubiquitin. As shown in Figure 7B (lane 2), UIM\textsuperscript{RAP80} was able to bind Ub2-7. To determine whether UIM\textsuperscript{RAP80} could direct monoubiquitination of proteins that contain this sequence, we analyzed the level of ubiquitination of EGFP and a EGFP–UIM\textsuperscript{RAP80} chimeric fusion protein in HeLa cells transfected with or without pCMV–HA–Ub, encoding HA-tagged ubiquitin. As shown in Figure 7C, EGFP–UIM\textsuperscript{RAP80} was ubiquitinated in HeLa cells only when HA–Ub was co-expressed. EGFP was not ubiquitinated either in the presence or absence of HA–Ub expression. These observations suggest that UIM\textsuperscript{RAP80} is able to direct ubiquitination and, therefore, behaves as a functional UIM.

Role of UIMs on RAP80 ubiquitination

UIM-containing proteins have been reported to become (multi)monoubiquitinated (31,36). To determine whether RAP80 was subject to ubiquitination, we examined the ubiquitination of RAP80 in HEK293 cells treated with and without the proteasome inhibitor MG132. Two major ubiquitinated RAP80 proteins migrating at about 120 and 135 kD and referred to as Ub–RAP80 and (Ub)\textsubscript{2}–RAP80, were detected (Figure 8A). Previous studies have shown that treatment with the proteasome inhibitor MG132 results in an accumulation of cellular polyubiquitinated proteins that are otherwise rapidly degraded by the proteasome system, whereas MG132 has little effect on monoubiquitinated proteins (21,31,32,37,38). Our data show that MG132 treatment had little effect on RAP80 ubiquitination (Figure 8A) suggesting that RAP80 itself is not polyubiquitinated to a great extent or rapidly degraded by the proteasome. Therefore, the two ubiquitinated RAP80 proteins likely represent RAP80 conjugated to one or two monoubiquitins. The effect of Nedd8, a ubiquitin homolog, was analyzed to further examine the specificity of the ubiquitination of RAP80. These data showed that RAP80 was not neddylation (not shown).

The UIMs in RAP80 contain two lysine residues (K\textsuperscript{90} and K\textsuperscript{112}) that are potential ubiquitination sites. To determine whether these sites are important for the multi-ubiquitination of RAP80, the effect of point mutations in these residues on RAP80 multi-ubiquitination was examined. None of the lysine mutants, K\textsuperscript{90}R, K\textsuperscript{112}R, or the double mutant K\textsuperscript{90,112}R, affected the degree of ubiquitination of RAP80 suggesting that K\textsuperscript{90} and K\textsuperscript{112} are not substrates of monoubiquitination (Figure S3).

Further evidence for the role of UIM\textsuperscript{RAP80} in the monoubiquitination of RAP80 came from experiments analyzing the ubiquitination of the amino terminus of RAP80. RAP80\textsubscript{ΔC122}, containing the amino terminus including UIM\textsuperscript{RAP80}, was ubiquitinated whereas RAP80\textsubscript{ΔC78}, lacking the UIM\textsuperscript{RAP80} was not suggesting that the UIM is required for RAP80 ubiquitination (Figure 8B). In the absence of exogenous HA–ubiquitin, the anti-FLAG antibody recognized several bands likely representing multi-ubiquitinated RAP80\textsubscript{ΔC122} conjugated with endogenous ubiquitin. No such bands were observed with RAP80\textsubscript{ΔC78}.

A88 and A113 are highly conserved among UIMs of different proteins (Figure 7A), and have been reported to be important for UIM function (39). We, therefore, examined the effect of the A88S, A113S and the A88,113S double mutation on the ubiquitination of RAP80\textsubscript{ΔC122}. Our data showed that the single mutations diminished RAP80 mult ubiquitination, while the double mutant A88,113S caused a more pronounced decrease in ubiquitination (Figure 8C). The results are in agreement with the conclusion that UIM\textsuperscript{RAP80} is required for the multi-monoubiquitination of the amino terminus of RAP80.

The UIMs of RAP80 are critical for its effects on ER\textsubscript{a}

Next, we investigated the importance of the UIM\textsuperscript{RAP80} on the interaction of RAP80 with ER\textsubscript{a}. First, we examined whether deletion of UIM\textsuperscript{RAP80} had any effect on the subcellular localization of RAP80. Full-length FLAG–RAP80 or FLAG–RAP80\textsubscript{ΔUIM1,2} was transiently expressed in HeLa cells and their subcellular localization examined by confocal microscopy. Figure S4 shows that both FLAG–RAP80 and RAP80\textsubscript{ΔUIM1,2} were localized to the nucleus.

To determine whether the UIMs play a role in the interaction between RAP80 and ER\textsubscript{a}, HeLa cells were co-transfected with pCDNA3.1–ER\textsubscript{a}–Myc-His and pLXIN–3×FLAG–RAP80 expression plasmids encoding either full-length RAP80 or several UIM deletion mutants of RAP80. Co-immunoprecipitation analysis showed that deletion of a single UIM or both UIMs did not abrogate the interaction between RAP80 and ER\textsubscript{a} (Figure S5).

To determine whether UIM\textsuperscript{RAP80} was required for the observed increase in the level of ER\textsubscript{a} protein by RAP80, the effects of RAP80 and RAP80\textsubscript{ΔUIM1,2} on the level of ER\textsubscript{a} protein were compared. HeLa cells expressing pER\textsubscript{a} only contained low levels of ER\textsubscript{a} protein. RAP80 significantly enhanced ER\textsubscript{a} levels (Figure 9A), whereas RAP80\textsubscript{ΔUIM1,2} only slightly increased the level of ER\textsubscript{a} protein. Expression of HA–Ub caused a further increase in the level of ER\textsubscript{a} protein. These data suggest that the UIM\textsuperscript{RAP80} is required for the increase in ER\textsubscript{a} protein level induced by RAP80.

Previous studies have shown that ER\textsubscript{a} is degraded by the ubiquitin–proteasome pathway (14,16,20). Since UIMs have been implicated in ubiquitin binding and in the modulation of ubiquitination (31), this raised the question of whether RAP80 affected ER\textsubscript{a} ubiquitination.
Figure 7. RAP80 contains two functional ubiquitin-interacting motifs (UIMs). (A) Sequence comparison of the UIM1 and UIM2 of RAP80 with those of epsin, hepatocyte growth factor-regulated tyrosine kinase substrate (HGS), the proteasome subunit PSMD4, the ubiquitin-specific peptidase 25 (USP25) and the consensus UIM sequence (Φ is a hydrophobic residue, ε is a negatively charged residue and x is any amino acid). (B) UIM\text{RAP80} is able to bind ubiquitin. GST (lane 1) or a GST–UIM\text{RAP80} fusion protein (lane 2) was bound to glutathione-Sepharose 4B beads and then incubated with 500 ng of purified Ub2-7. After 1 h incubation, beads were washed extensively and bound proteins solubilized. Bound proteins were examined by western blot analysis with anti-Ub antibody (upper panel). The input for GST and GST–UIM\text{RAP80} was also shown (lower panel). (C) UIM\text{RAP80} promotes monoubiquitination of EGFP–UIM\text{RAP80}. pEGFP or pEGFP–UIM\text{RAP80} was transfected in HeLa cells with or without pCMV–HA–Ub. Forty-eight hours later, the EGFP proteins were isolated with anti-GFP antibody. The proteins were separated with SDS-PAGE and blotted with anti-HA (upper panel) and anti-GFP (lower panel) antibodies respectively. The IgG\text{H} and a non-specific band (NS) are indicated.
Figure 8. Role of UIM\(^{\text{RAP80}}\) in RAP80 ubiquitination. (A) HEK293 cells were transfected with pLXIN–3×FLAG–RAP80, pCMV–HA–Ub as indicated. After 48 h incubation, cells were treated with or without 25 μM of MG132 for 4 h before cell lysates were prepared. Ubiquitinated proteins were isolated with anti-HA antibody and examined by western blot analysis with anti-FLAG antibody. The input RAP80 is shown in the lower panel. ‘ns’ indicates nonspecific pull-down. (B) UIM\(^{\text{RAP80}}\) promotes the ubiquitination of the amino terminus of RAP80. HeLa cells were transfected with pLXIN–3×FLAG–RAP80, pCMV–HA–Ub with or without pCMV–HA–Ub. Forty-eight hours later, FLAG–RAP80 was isolated with FLAG M2 resin and examined by western blot analysis with anti-HA and anti-FLAG antibodies. Non-specific staining of IgG is indicated on the right. (C) HEK293 cells were transfected with wild type or mutant pLXIN–3×FLAG–RAP80ΔC122 and pCMV–HA–Ub as indicated. Cells were treated and processed as described under A.

Figure 9. Role of UIM\(^{\text{RAP80}}\) on the interaction of RAP80 with ER\(_\alpha\). (A) UIM is required for the RAP80-induced increase in the level of ER\(_\alpha\) protein. HeLa cells were transfected with pLXIN–3×FLAG–RAP80, pER\(_\alpha\) and pCMV–HA–Ub. Forty-eight hours after transfection, cells were collected and protein cell lysates examined by western blot analysis using anti-ER\(_\alpha\), anti-FLAG M2 and anti-actin antibodies. (B) Effect of RAP80 on ER\(_\alpha\) polyubiquitination. HeLa cells were transfected with pcDNA3–ER\(_\alpha\)–Myc-His, wild type pLXIN–3×FLAG–RAP80 or FLAG–RAP80 and pCMV–HA–Ub for 48 h and treated with or without E2 for 24 h. The cells were treated with MG132 for 4 h before collection and ER\(_\alpha\) proteins immunoprecipitated with an anti-ER\(_\alpha\) antibody. Western blot was performed with an anti-HA or anti-ER\(_\alpha\) antibody to detect ER\(_\alpha\) ubiquitination and the level of immunoprecipitated ER\(_\alpha\), respectively. The level of FLAG–RAP80 expression was determined with anti-FLAG M2 antibody (lower panel). (C) UIM is required for the RAP80-induced increase in ER\(_\alpha\)-mediated transactivation. MCF-7 cells were transfected with different amounts of pLXIN–3×FLAG–RAP80 or pLXIN–3×FLAG–RAP80ΔUIM1,2 and then treated with 100 nM E2 or ethanol for 24 h. Cells were collected and assayed for luciferase activity. The relative Luc activity was calculated and plotted. RAP80 expression was also detected with anti-FLAG M2 antibody (lower panels).
To examine this, HeLa cells were transfected with pcDNA3.1–ERz–Myc-His, pCMV–HA–ubiquitin and pLXIN–3×FLAG–RAP80 or pLXIN–3×FLAG–RAP80ΔUIM1,2. Cells were treated with MG132 for 4h before protein extracts were prepared and protein complexes immunoprecipitated with an anti-ERz antibody. The protein complexes were subsequently examined by western blot analysis with anti-HA antibody to detect complexes immunoprecipitated with an anti-ERz antibody. The protein levels were observed in the experiment described in Figure 10C and may be due to the high expression of ERz induced by pcDNA3.1–ERz–Myc-His. RAP80 did not affect ERz ubiquitination in the absence of E2 (Figure 9B) or in the presence of tamoxifen (data not shown). The latter is in agreement with the demonstration that interaction of RAP80 with ERz is dependent on the presence of an agonist.

We next examined whether UIMRAP80 was required for the modulation of ERz-mediated transcriptional activation by RAP80. MCF-7 cells were co-transfected with an ERz-Luc reporter plasmid and different amounts of pLXIN–3×FLAG–RAP80 or pLXIN–3×FLAG–RAP80ΔUIM1,2. In the absence of E2, both RAP80 and RAP80ΔUIM1,2 had little effect on Luc reporter activity. Addition of E2 induced ERz-mediated transcriptional activation by endogenous ERz; this activation was enhanced by increased expression of RAP80. In contrast, expression of the RAP80ΔUIM1,2 mutant did not augment ERz-mediated activation of the reporter (Figure 9C). These results indicate that UIMRAP80 is critical for the modulation of ERz activity by RAP80.

DISCUSSION

In this study, we identify ERz as a new RAP80-interacting protein. The interaction of RAP80 with nuclear receptors is very selective since a number of receptors, including ERβ, PPARγ, RORγ and ERz were unable to interact with RAP80 either in the presence or absence of their corresponding ligand. The interaction of RAP80 with ERz is dependent on the presence of an ERz agonist, as E2 and E3, promoted this interaction whereas the antagonists ICI 182,780 and tamoxifen did not. Previous studies have shown that binding of an agonist to the ligand-binding pocket of ERz induces a conformational change in the receptor. This involves a repositioning of helix 12 that allows recruitment of co-activators that subsequently mediate the transcriptional activation of ERz target genes by ERz (3,6,40). Binding of an antagonist induces a conformational change that results in the recruitment of co-repressors rather than co-activators. The dependency of the interaction of RAP80 with ERz on agonist binding indicates that RAP80 interacts with the transcriptionally active conformation of ERz.

The interaction between RAP80 and ERz was confirmed by mammalian two-hybrid analysis and co-immunoprecipitation. In vitro pull-down analysis with GST–RAP80 protein demonstrated that RAP80 interacted with full-length ERz, ERzΔN180 (containing the DBD, hinge domain and LBD), and with ERzΔN248 (containing the hinge and LBD), but did not interact with ERzΔC248 (containing the amino terminus, including the DBD). These observations suggest that RAP80 and ERz physically interact with each other and indicate that the amino terminus and DBD of ERz are not an absolute necessity for this interaction. The requirement of the LBD of ERz is in agreement with our observation that the interaction is ligand dependent. Thus, ligand-induced changes could unmask binding motifs in ERz required for its interaction with RAP80.

To determine which domain in RAP80 is required for its interaction with ERz, the effect of various mutations in RAP80 on this interaction was examined. Analysis of a series of carboxyl-terminal deletions showed that the zinc finger motifs are not required for the interaction of RAP80 with ERz, but that the region between aa 304 and 404 is essential. A number of transcriptional mediators have been reported to interact with the LBD of agonist-bound ERz through a sequence containing an LXXLL consensus motif (3,41–43). RAP80 contains two related sequences 296ILCQL and 625LLSFL. However, deletion of 625LLSFL or mutation of 296ILCQL into 296ISCQL did not affect the interaction of RAP80 with ERz (not shown) suggesting that the interaction of RAP80 with ERz involves a different sequence.

In addition to the two zinc finger motifs, we identified two putative UIMs at the amino terminus of RAP80 that exhibit high homology to the consensus UIM eexxΦxxAxxxSxxexxxx (in which Φ is a hydrophobic residue, e is a negatively charged residue and x is any amino acid) (Figure 7A) (31,32). Several studies have shown that UIMs often mediate the monoubiquitination of proteins that contain these sequences (31,35,36,44). In addition, UIMs have been reported to bind ubiquitin and as such mediate intra- or intermolecular interactions by interacting with ubiquitinated target proteins or proteins containing a ubiquitin-like domain (30,31,35,36,45). Analysis of the UIMRAP80 demonstrated that RAP80 was able to bind polyubiquitin chains of different lengths and to varying degrees. In addition, UIMRAP80 was able to promote the monoubiquitination of a chimeric EGFP–UIMRAP80 protein and the amino terminus of RAP80 while no ubiquitination was observed when the UIMRAP80 was deleted. In addition, point mutations in A88 and A113, alanines that are highly conserved among UIMs, greatly diminish ubiquitination of RAP80 (Figure 8C) in agreement with previous observations (39). Although the UIMRAP80 contains two lysines, mutations of these lysines had little effect on RAP80 ubiquitination suggesting that they are not substrates for monoubiquitination. This is in agreement with reports indicating that lysines within
UIMs are generally not monoubiquitinated (31). Based on the calculated size of ubiquitinated RAP80 (Figure 8A), it was concluded that several lysines may become monoubiquitinated. These observations support the conclusion that the UIM\textsuperscript{RAP80} domain in RAP80 is functional and able to guide monoubiquitination of RAP80 and, in addition, is able to bind ubiquitin. We propose that the UIM\textsuperscript{RAP80} domain mediates a signal that is critical to the function of RAP80.

Although the mechanisms of protein polyubiquitination and their role in targeting proteins to proteasomes for degradation have been intensively studied, the role of (multi)monoubiquitination is not as well understood (21,32,33,46). Monoubiquitination functions as a signal that affects the structure, activity or localization of the target protein, thereby regulating a broad range of cellular functions, including membrane protein trafficking, histone function, transcriptional regulation, DNA repair and replication. UIMs are required for the (multi)monoubiquitination of several proteins, such as epsin, Eps15, and Eps15R, involved in receptor endocytosis (33,37,44,47). These proteins play a critical role in the recruitment of plasma membrane receptor proteins to clathrin-coated pits and their internalization. Deletion or mutation in these UIMs greatly impacts the internalization of membrane receptors (48). A recent study provided evidence for an intramolecular interaction between monoubiquitin and the UIM in Eps15 and Hrs that prevents them to interact with ubiquitinated membrane receptors, thereby affecting their trafficking (37). Since RAP80 is a nuclear protein, it is likely not involved in membrane receptor endocytosis. Monoubiquitination has been reported to be involved in the regulation of several nuclear functions. For example, monoubiquitination of histones does not target them for degradation but has a role in the regulation of chromatin remodeling and transcriptional regulation (49,50). Monoubiquitination is also critical in DNA repair (51). For example, the subunit S5a (Rpn10) of the 19S proteosomal regulatory complex contains two UIMs that interact with the ubiquitin-like (Ubl) domain of RAD23B (HR23B), a protein that targets several proteins to the proteasome, including the excision repair factor XPC (30,32).

Monoubiquitination can also affect the localization of proteins (30,52). However, deletion of the UIMs in RAP80 does not affect its nuclear localization. In addition, our data show that the UIMs are not required for the interaction of RAP80 with ER\textsubscript{\alpha}, but are critical to the effects of RAP80 on ER\textsubscript{\alpha} function. Since several UIM-containing proteins have been reported to be involved in ubiquitination or ubiquitin metabolism, we examined whether RAP80 had any effect on the ubiquitination of ER\textsubscript{\alpha}. Our results demonstrate that increased expression of RAP80 decreases the ubiquitination of ER\textsubscript{\alpha}. Although the UIMs were not required for the interaction of RAP80 with ER\textsubscript{\alpha}, deletion of UIM\textsuperscript{RAP80} eliminates RAP80's capacity to inhibit ER\textsubscript{\alpha} ubiquitination suggesting that the UIM\textsuperscript{RAP80} is essential for the effect of RAP80 on ER\textsubscript{\alpha} ubiquitination. What the functions of ubiquitination of nuclear receptors are, is still controversial and not yet completely understood (21). Ubiquitination of ER\textsubscript{\alpha} appears to have multiple functions and can affect ER\textsubscript{\alpha} protein levels and turnover and ER\textsubscript{\alpha}-mediated transcriptional regulation at different steps in the ER\textsubscript{\alpha} signaling pathway (14,16,53). One function of ER\textsubscript{\alpha} polyubiquitination is related to targeting misfolded, unliganded ER\textsubscript{\alpha} for degradation by the proteasome system. This involves binding of the Hsc70-interacting protein (CHIP) which, through its E3 ubiquitin ligase activity, ubiquitinates ER\textsubscript{\alpha} (16,54). Another role of ER\textsubscript{\alpha} ubiquitination relates to transcriptional regulation. Several studies have shown that in the presence of agonist, ER\textsubscript{\alpha} is rapidly degraded by the proteasome system (14,17,20). This turnover of ER\textsubscript{\alpha} appears to be important for efficient ER\textsubscript{\alpha}-dependent transcriptional activation. Such a coupling between protein degradation and transactivation might be an integral part of nuclear receptor function. However, overexpression of proteasome 26S subunit PSMC5 (SUG1) enhances the ubiquitination of ER\textsubscript{\alpha} in the presence of agonist and inhibited transcriptional activation (55). In addition, Fan et al. (56) reported that inhibition of proteasome degradation by the proteasome inhibitor MG132 enhanced ER\textsubscript{\alpha}-mediated transcriptional activation. These studies suggest that there is a delicate balance between level of ER\textsubscript{\alpha} protein and transcriptional activation.

Our results show that expression of RAP80 enhances ER\textsubscript{\alpha}-mediated transcriptional activation possibly by causing an increase in ER\textsubscript{\alpha} protein levels. The latter may be related to the reduced ER\textsubscript{\alpha} ubiquitination and degradation. We show that the effects of RAP80 on ER\textsubscript{\alpha} were dependent on UIM\textsuperscript{RAP80}, supporting our hypothesis that this domain is critical to the function of RAP80. The effects of RAP80 on ER\textsubscript{\alpha} are very similar to those recently reported for MUC1 (8). MUC1 was shown to stabilize ER\textsubscript{\alpha} by inhibiting its ubiquitination (8). The carboxyl-terminal subunit of MUC1 was shown to associate with ER\textsubscript{\alpha} complexes on estrogen-responsive promoters and to stimulate ER\textsubscript{\alpha}-mediated transcription. MUC1 mediates this action by directly binding to the DBD of ER\textsubscript{\alpha} in an agonist-dependent manner. These different findings indicate the complex role of ubiquitination in the regulation of ER\textsubscript{\alpha} function (14,53).

In summary, in this study we identify ER\textsubscript{\alpha} as a new RAP80-interacting protein and show that this interaction is dependent on ER\textsubscript{\alpha} agonist binding. We demonstrate that RAP80 is a UIM-containing protein with two functional UIMs that are able to bind ubiquitin and direct monoubiquitination. These UIMs are not required for its interaction with ER\textsubscript{\alpha} but appear necessary for the decrease in ER\textsubscript{\alpha} polyubiquitination and the increase in ER\textsubscript{\alpha}-mediated transcriptional activation induced by RAP80. Our observations show that the UIM\textsuperscript{RAP80} is critical for the function of RAP80 and suggests that RAP80 is an important modulator of ER\textsubscript{\alpha}. 
SUPPLEMENTARY DATA

Supplementary Data is available at NAR Online.

ACKNOWLEDGMENTS

The authors would like to thank Drs Bonnie Deroo, John Couse, and Erica Allen for their valuable comments on the manuscript. This research was supported by the Intramural Research Program of the NIEHS, NIH.

REFERENCES

1. Hewitt,S.C. and Korach,K.S. (2003) Oestrogen receptor knockout mice: roles for oestrogen receptors alpha and beta in reproductive tissues. Reproduction, 125, 143–149.
2. Wallace,O.B., Richardson,T.I. and Dodge,J.A. (2003) Estrogen receptor modulators: relationships of ligand structure, receptor affinity and functional activity. Curr. Top. Med. Chem., 3, 1663–1682.
3. Nilsson,S., Makela,S., Treutler,E., Tujague,M., Thomsen,J., Andersson,G., Enmark,E., Pettersson,K., Warner,M. and Gustafsson,J.A. (2001) Mechanisms of estrogen action. Physiol. Rev., 81, 1535–1565.
4. Sanchez,R., Nguyen,D., Rocha,W., White,J.H. and Mader,S. (2002) Coactivator and corepressor complexes in nuclear receptor function. Curr. Opin. Genet. Dev., 9, 140–147.
5. Xu,L., Glass,C.K. and Rosenfeld,M.G. (1999) Coactivator and corepressor complexes in nuclear receptor function. Curr. Opin. Genet. Dev., 9, 140–147.
6. Raft,M., Gangloff,M., Wurtz,J.M. and Moras,D. (2000) Estrogen receptor transcription and transactivation: structure-function relationship in DNA- and ligand-binding domains of estrogen receptors. Breast Cancer Res., 2, 353–359.
7. McKenna,N.J., Xu,J., Nawaz,Z., Tsai,S.Y., Tsai,M.J. and O'Malley,B.W. (1999) Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. J. Steroid Biochem. Mol. Biol., 69, 3–12.
8. Wei,X., Xu,H. and Kufe,D. (2006) MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol. Cell, 21, 295–305.
9. Kobayashi,S., Shibata,H., Yokota,K., Suda,N., Murai,A., Kurihara,I., Saito,I. and Saruta,T. (2004) FHL2, UBC9, and PIAS1 are novel estrogen receptor alpha-interacting proteins. Endocr. Rev., 30, 617–621.
10. Norris,J.D., Fan,D., Sherk,A. and McDonnell,D.P. (2002) A negative coregulator for the human ER. Mol. Endocrinol., 16, 459–468.
11. Wu,L., Wu,Y., Gauthings,B., Wan,M., Li,X., Grizzle,W., Liu,Z., Lu,C., Mao,Z. and Cao,X. (2003) Smad4 as a transcription coexecutor for estrogen receptor alpha. J. Biol. Chem., 278, 15192–15200.
12. Fernandes,I., Bastien,Y., Wai,T., Nygard,N., Raman,R., Csermely,P., Mader,S., Han,V.K., Yang,X.J. and White,J.H. (2003) Ligand-dependent nuclear receptor coexecutor LCoR functions by histone deacetylase-dependent and -independent mechanisms. Mol. Cell, 11, 139–150.
13. Poukka,H., Aarnisalo,P., Karvonen,U., Palvimo,J.J. and Janne,O.A. (1999) Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription. J. Biol. Chem., 274, 19441–19446.
14. Nawaz,Z., Lonard,D.M., Dennis,A.P., Smith,C.L. and O'Malley,B.W. (1999) Proteasome-dependent degradation of the human estrogen receptor. Proc. Natl. Acad. Sci. U.S.A., 96, 1858–1862.
15. Henrich,L.M., Smith,J.A., Kitt,D., Errington,T.M., Nguyen,B., Traish,A.M. and Lannigan,D.A. (2003) Extracellular signal-regulated kinase 7, a regulator of hormone-dependent estrogen receptor destruction. Mol. Cell. Biol., 23, 5979–5988.
16. Tateshii,Y., Kawabe,Y., Chiba,T., Murata,S., Ichikawa,K., Murayama,A., Tanaka,K., Baba,T., Kato,S. and Yanagisawa,J. (2004) Ligand-dependent switching of ubiquitin-proteasome pathways for estrogen receptor. EMBO J., 23, 4813–4823.
17. Lonard,D.M., Nawaz,Z., Smith,C.L. and O'Malley,B.W. (2000) The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol. Cell, 5, 939–948.
18. Liang,M. and Nilsson,B.O. (2004) Proteasome-dependent degradation of ERalpha but not ERbeta in cultured mouse aorta smooth muscle cells. Mol. Cell. Endocrinol., 224, 65–71.
19. Nirmala,P.B. and Thompan,R.V. (1995) Ubiquitination of the rat uterine estrogen receptor: dependence on estradiol. Biochem. Biophys. Res. Commun., 213, 24–31.
20. Reid,G., Hubner,M.R., Metivier,R., Brand,H., Denger,S., Manu,D., Beaudouin,J., Ellenberg,J. and Gannon,F. (2003) Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol. Cell, 11, 695–707.
21. Kinyamu,H.K., Chen,J. and Archer,T.K. (2005) Linking the ubiquitin-proteasome pathway to chromatin remodeling/modification by nuclear receptors. J. Mol. Endocrinol., 34, 281–297.
22. Lee,J.W., Ryan,F., Swaffield,J.C., Johnston,S.A. and Moore,D.D. (1995) Interaction of thyroid-hormone receptor with a conserved transcriptional mediator. Nature, 374, 1–9.
23. Imhof,M.O. and McDonnell,D.P. (1996) Yeast RSP5 and its human homolog hRPF1 potentiate hormone-dependent activation of transcription by human progesterone and glucocorticoid receptors. Mol. Cell. Biol., 16, 2594–2605.
24. Verma,S., Ismiail,A., Gao,X., Fu,G., Li,X., O'Malley,B.W. and Nawaz,Z. (2004) The ubiquitin-conjugating enzyme UBC17 acts as a coactivator for steroid hormone receptors. Mol. Cell. Biol., 24, 8716–8726.
25. Sentis,S., Le Romancer,M., Bianchin,C., Rostan,M.C. and Corbo,L. (2005) Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol. Endocrinol., 19, 2671–2684.
26. Yan,Z., Kim,Y.S. and Jeitzen,A.M. (2002) RAP80, a novel nuclear protein that interacts with the retinoid-related testis-associated receptor. J. Biol. Chem., 277, 32379–32388.
27. Lei,W., Hirose,T., Zhang,L.X., Adachi,H., Spinella,M.J., Dmitrovsky,E. and Jeitzen,A.M. (1997) Cloning of the human orphan receptor germ cell nuclear factor/retinoid receptor-related testis-associated receptor and its differential regulation during embryonal carcinoma cell differentiation. J. Mol. Endocrinol., 18, 167–176.
28. Chen,F., Cooney,A.J., Wang,Y., Law,S.W. and O'Malley,B.W. (1994) Cloning of a novel orphan receptor (GCNF) expressed during germ cell development. Mol. Endocrinol., 8, 1434–1444.
29. Hirose,T., O'Brien,D.A. and Jeitzen,A.M. (1995) RTR: a new member of the nuclear receptor superfamily that is highly expressed in murine testis. Gene, 152, 247–251.
30. Fujiwara,K., Tenno,T., Sugawara,K., Jee,J.G., Okh,i., Kojima,C., Tochio,H., Hiroaki,H., Hanaoka,F. and Shirakawa,M. (2004) Structure of the ubiquitin-interacting motif of Ssa5 bound to the ubiquitin-like domain of HR32B. J. Biol. Chem., 279, 4760–4767.
31. Miller,S.L., Malotky,E. and O'Bryan,J.P. (2004) Analysis of the role of ubiquitin-interacting motifs in ubiquitin binding and ubiquitylation. J. Biol. Chem., 279, 33528–33537.
32. Di Fiore,P.P., Polo,S. and Hofmann,K. (2003) When ubiquitin meets ubiquitin receptors: a signalling connection. Nat. Rev. Mol. Cell. Biol., 4, 491–497.
33. Katzmann,D.J., Odorizzi,G. and Emr,S.D. (2002) Receptor down-regulation and multisubcellular-body sorting. Nat. Rev. Mol. Cell. Biol., 3, 893–905.
34. Young,P., Deveraux,Q., Beal,R.E., Pickart,C.M. and Rechsteiner,M. (1998) Characterization of two polyubiquitin binding sites in the 26S protease subunit 5a. J. Biol. Chem., 273, 5461–5467.
35. Oldham,C.E., Mohney,R.P., Miller,S.L., Hanes,R.N. and O'Bryan,J.P. (2002) The ubiquitin-interacting motifs target the endocytic adaptor protein epsin for ubiquitination. Curr. Biol., 12, 1112–1116.
36. Klapisz,E., Sorokina,I., Lemeer,S., Pijnenburg,M., Verkleij,A.J. and van Bergen en Henegouwen,P.M.P. (2002) A ubiquitin-interacting motif (UIM) is essential for Eps15 and Eps15R ubiquitination. J. Biol. Chem., 277, 30746–30753.

37. Hoeller,D., Crosetto,N., Blagoev,B., Raiborg,C., Tikkanen,R., Wagner,S. and Dikic,I. (2006) Regulation of ubiquitin-binding proteins by monoubiquitination. Nat. Cell Biol., 8, 163–169.

38. Hofmann,K. and Falquet,L. (2001) A ubiquitin-interacting motif conserved in components of the proteasomal and lysosomal protein degradation systems. Trends Biochem. Sci., 26, 347–350.

39. Hirano,S., Kawasaki,M., Ura,H., Kato,R., Raiborg,C., Stenmark,H. and Wakatsuki,S. (2006) Double-sided ubiquitin binding of Hrs-UIM in endosomal protein sorting. Nat. Struct. Mol. Biol., 13, 272–277.

40. Brzozowski,A.M., Pike,A.C., Dauter,Z., Hubbard,R.E., Bonn,T., Engstroem,O., Ohman,L., Greene,G.L., Gustafsson,J.A. and Carlquist,M. (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature, 389, 753–758.

41. Chang,C., Norris,J.D., Gron,H., Paige,L.A., Hamilton,P.T., Kenan,D.J., Fowlkes,D. and McDonnell,D.P. (1999) Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta. Mol. Cell. Biol., 19, 8226–8239.

42. Shibata,H., Spencer,T.E., Onate,S.A., Jenster,G., Tsai,S.Y., Tsai,M.J. and O’Malley,B.W. (1997) Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog. Horm. Res., 52, 141–165.

43. Gagnon,M., Mull,M., Eiler,S., Duclair,S., Wurtz,J.M. and Moras,D. (2001) Crystal structure of a mutant hERalpha ligand-binding domain reveals key structural features for the mechanism of partial agonism. J. Biol. Chem., 276, 15059–15065.

44. Polo,S., Sigismund,S., Faretta,M., Guidi,M., Capua,M.R., Bossi,G., Chen,H., De Camilli,P. and Di Fiore,P.P. (2002) A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins. Nature, 416, 451–455.

45. Hicke,L., Schubert,H.L. and Hill,C.P. (2005) Ubiquitin-binding domains. Nat. Rev. Mol. Cell. Biol., 6, 610–621.

46. Fang,S. and Weissman,A.M. (2004) A field guide to ubiquitylation. Cell. Mol. Life Sci., 61, 1546–1561.

47. Shih,S.C., Prag,G., Francis,S.A., Satunto,M.A., Hurley,J.H. and Hicke,L. (2003) A ubiquitin-binding motif required for intramolecular monoubiquitlation, the CUE domain. EMBO J., 22, 1273–1281.

48. Barriere,H., Nemes,C., Lechardueur,D., Khan-Mohammad,M., Fruh,K. and Lukacs,G.L. (2006) Molecular basis of oligoubiquitin-dependent internalization of membrane proteins in mammalian cells. Traffic, 7, 282–297.

49. Nickel,B.E. and Davie,J.R. (1989) Structure of polyubiquitinated histone H2A. Biochemistry, 28, 964–968.

50. Sun,Z.W. and Allis,C.D. (2002) Ubiquitination of histone H2B regulates H3 methylation and gene silencing in yeast. Nature, 418, 104–108.

51. Huang,T.T. and D’Andrea,A.D. (2006) Regulation of DNA repair by ubiquitylation. Nat. Rev. Mol. Cell. Biol., 7, 323–334.

52. Nabhan,J.F. and Ribeiro,P. (2006) The 19S proteasomal subunit POH1 contributes to the regulation of c-Jun ubiquitination, stability and subcellular localization. J. Biol. Chem, 281, 16099–16107.

53. Zhang,H., Sun,L., Liang,J., Yu,W., Zhang,Y., Wang,Y., Chen,Y., Li,R., Sun,X. and Shang,Y. (2006) The catalytic subunit of the proteasome is engaged in the entire process of estrogen receptor-regulated transcription. EMBO J., 25, 4223–4233.

54. Fan,M., Park,A. and Nephew,K.P. (2005) CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha. Mol. Endocrinol., 19, 2901–2914.

55. Masuyama,H. and Hiramatsu,Y. (2004) Involvement of suppressor for Gal 1 in the ubiquitin/proteasome-mediated degradation of estrogen receptors. J. Biol. Chem., 279, 12020–12026.

56. Fan,M., Nakshatri,H. and Nephew,K.P. (2004) Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation. Mol. Endocrinol., 18, 2603–2615.